Article
A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes.
Cellular oncology : the official journal of the International Society for Cellular Oncology - 1 Jan 2009
Heideman D A M, Thunnissen F B, Doeleman M, Kramer D, Verheul H M, Smit E F, Postmus P E, Meijer C J L M, Meijer G A, Snijders P J F
Abstract excerpt
BACKGROUND: Increasing data from clinical trials support EGFR and K-ras mutation status as predictive markers of tumour response to EGFR-targeted therapies. Consequently, rapid and reliable mutation screening assays are demanded to guide rational use of EGFR-targeted therapies. METHODS: In this study, we describe the development of high resolution melting (HRM) technology-based assays with direct sequencing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.